About: EUAdb: a resource for COVID-19 test development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: EUAdb: a resource for COVID-19 test development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	EUAdb: a resource for COVID-19 test development
Creator	Boeke, Jef Fitch, David Kiontke, Karin Laurent, Jon Shaffer, Henry Woronik, Alyssa Zambrano, Ronald
Source	BioRxiv; Medline
abstract	Due to the sheer number of COVID-19 (coronavirus disease 2019) cases, the prevalence of asymptomatic cases and the fact that undocumented cases appear to be significant for transmission of the causal virus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), there is an urgent need for increased SARS-CoV-2 testing capability that is both efficient and effective1. In response to the growing threat of the COVID-19 pandemic in February, 2020, the FDA (US Food and Drug Administration) began issuing Emergency Use Authorizations (EUAs) to laboratories and commercial manufacturers for the development and implementation of diagnostic tests1. So far, the gold standard assay for SARS-CoV-2 detection is the RT-qPCR (real-time quantitative polymerase chain reaction) test2. However, the authorized RT-qPCR test protocols vary widely, not only in the reagents, controls, and instruments they use, but also in the SARS-CoV-2 genes they target, what results constitute a positive SARS-CoV-2 infection, and their limit of detection (LoD). The FDA has provided a web site that lists most of the tests that have been issued EUAs, along with links to the authorization letters and summary documents describing these tests1. However, it is very challenging to use this site to compare or replicate these tests for a variety of reasons. First, at least 12 of 18 tests for EUA submissions made prior to March 31, 2020, are not listed there. To our knowledge, no EUAs have been issued for these applications. Second, the data are not standardized and are only provided as longhand prose in the summary documents. Third, some details (e.g. primer sequences) are absent from several of the test descriptions. Fourth, for tests provided by commercial manufacturers, summary documents are completely missing. To address at least the first three issues, we have developed a database, EUAdb (EUAdb.org), that holds standardized information about EUA-issued tests and is focused on RT-qPCR diagnostic tests, or “high complexity molecular-based laboratory developed tests”1. By providing a standardized ontology and curated data in a relational architecture, we seek to facilitate comparability and reproducibility, with the ultimate goal of consistent, universal and high-quality testing nationwide. Here, we document the basics of the EUAdb data architecture and simple data queries. The source files can be provided to anyone who wants to modify the database for his/her own research purposes. We ask that the original source of the files be made clear and that the database not be used in its original or modified forms for commercial purposes.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1101/2020.07.30.228890
bibo:pmid	32766578
has license	biorxiv
sha1sum (hex)	bf3cedbfd5b7c46bea9a702fbc5ded13a47516cd
schema:url	https://doi.org/10.1101/2020.07.30.228890
resource representing a document's title	EUAdb: a resource for COVID-19 test development
has PubMed identifier	32766578
schema:publication	bioRxiv
resource representing a document's body	covid:bf3cedbfd5b7c46bea9a702fbc5ded13a47516cd#body_text
is schema:about of	named entity 'original' named entity 'replicate' named entity 'ontology' named entity 'COVID-19' named entity 'data' named entity 'standardized' named entity 'LoD' named entity 'clear' named entity 'authorized' named entity 'links' named entity 'reagents' named entity 'detection' named entity 'sequences' named entity 'FDA' named entity 'manufacturers' named entity 'LIMIT OF DETECTION' named entity 'REASONS' named entity 'SIGNIFICANT' named entity 'APPEAR' named entity 'APPLICATIONS' named entity 'DETECTION' named entity 'DATA ARCHITECTURE' named entity 'USE' named entity 'SOURCE' named entity 'TIME' named entity 'DOCUMENT ' named entity 'FORMS' named entity 'COVID-19' named entity 'KNOWLEDGE' named entity 'INFORMATION' named entity 'VARIETY' named entity 'ABSENT' named entity 'SEQUENCES' named entity 'HERE' named entity 'FOURTH' named entity 'BUT' named entity 'TEST' named entity 'THEIR' named entity 'TARGET' named entity 'OUR' named entity '2019' named entity 'SUMMARY' named entity 'PROSE' named entity 'DEVELOPMENT' named entity 'THESE' named entity 'INSTRUMENTS' named entity 'LABORATORY' named entity 'MODIFIED' named entity 'THREAT' named entity 'GOLD STANDARD' named entity 'HIGH' named entity 'FACT' named entity 'NUMBER OF' named entity 'REPRODUCIBILITY' named entity 'DESCRIPTIONS' named entity 'tests' named entity 'basics' named entity 'positive' named entity 'coronavirus disease 2019' named entity 'tests' named entity 'describing' named entity 'longhand' named entity 'Administration' named entity 'complexity' named entity 'genes' named entity 'reasons' named entity 'web site' named entity 'RT-qPCR' named entity 'COVID-19' named entity 'detection' named entity 'development' named entity 'documents' named entity 'prior' named entity 'Emergency' named entity 'RT-qPCR' named entity 'reproducibility'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software